Estrella Immunopharma (ESLA) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed TScan Therapeutics (TCRX) over the past year, losing 67.9% versus a loss of 88.5%. Over five years, ESLA leads with a -95.8% price change compared with -96.6% for TCRX. Estrella Immunopharma is the larger company by market cap ($16.7 million vs $16.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | TCRX |
|---|---|---|
| Share price | $0.3829 | $0.2366 |
| Market cap | $16.66M | $16.04M |
| 1-day change | -8.29% | +3.78% |
| YTD return | -73.24% | -77.18% |
| 1-year return | -67.88% | -88.47% |
| 5-year return | -95.77% | -96.62% |
| EPS (TTM) | $-0.25 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $2.57 |
| 52-week low | $0.3083 | $0.224 |
| Distance from 52-week high | -87.84% | -90.79% |
| Analyst consensus | none | hold |
| Avg. price target upside | +3033.98% | +322.65% |
| Average volume | 38.61K | 783.59K |
| Shares outstanding | 43.50M | 63.50M |
| Employees | — | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed TCRX by 20.6 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
ESLA vs TCRX FAQ
Which is bigger, Estrella Immunopharma or TScan Therapeutics?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $16.66M compared with $16.04M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, ESLA or TCRX?
ESLA returned -67.88% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.